Tenaya Therapeutics (NASDAQ:TNYA) Releases Earnings Results, Beats Expectations By $0.02 EPS

Tenaya Therapeutics (NASDAQ:TNYA) released its earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02, FiscalAI reports. The business had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $0.80 million.

Tenaya Therapeutics Trading Up 2.7%

Shares of TNYA traded up $0.01 during mid-day trading on Wednesday, hitting $0.37. The company’s stock had a trading volume of 1,602,720 shares, compared to its average volume of 3,456,521. The firm has a market capitalization of $84.31 million, a price-to-earnings ratio of -0.70 and a beta of 2.88. The company’s 50-day moving average is $0.56 and its 200-day moving average is $0.71. Tenaya Therapeutics has a 52-week low of $0.35 and a 52-week high of $1.56.

Wall Street Analyst Weigh In

TNYA has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Monday, October 26th. Wall Street Zen raised shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tenaya Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.